近日，天域生物科技有限公司发布公告称，公司董事长罗卫国因个人工作安排调整，已正式向董事会提交辞呈，并即日起不再担任公司董事长及董事会相关职务。公告强调，罗卫国的辞职不会影响公司正常经营，目前公司治理结构稳定，各项业务有序推进。董事会将尽快按照法定程序选举新任董事长。罗卫国自公司创立以来长期担任核心管理职务，在其领导下，天域生物在细胞治疗、基因编辑等前沿生物技术领域取得多项突破，并成功推动多个创新药物进入临床阶段。业内普遍认为，他的战略眼光和科研背景为公司早期发展奠定了坚实基础。尽管此次辞职引发市场一定关注，但公司表示管理层交接平稳，未来将继续聚焦核心技术研发与商业化落地。值得注意的是，罗卫国并未完全退出公司，仍将以顾问身份参与部分战略项目。这一安排有助于保障公司技术路线的连续性，也为新管理层提供过渡支持。投资者可关注后续董事会换届进展及公司战略方向是否发生调整。
Recently, Tianyu Biotechnology Co., Ltd. announced that Chairman Luo Weiguo has formally submitted his resignation to the board of directors due to adjustments in his personal work arrangements, effective immediately. The company emphasized that Mr. Luo’s departure will not affect normal operations, as the current governance structure remains stable and business activities continue as planned. The board will promptly initiate procedures to appoint a new chairman in accordance with corporate governance regulations.Since the company’s inception, Luo Weiguo has held key leadership roles and played a pivotal role in advancing Tianyu Bio’s breakthroughs in cutting-edge fields such as cell therapy and gene editing, successfully steering multiple innovative drug candidates into clinical trials. Industry observers widely credit his strategic vision and scientific expertise for laying a solid foundation during the company’s formative years. Although the resignation has drawn market attention, management confirmed a smooth transition and reaffirmed its commitment to core R&D and commercialization efforts.Notably, Luo will remain involved as a strategic advisor on select projects, ensuring continuity in the company’s technological roadmap and providing support during the leadership transition. Investors should monitor upcoming board appointments and any potential shifts in corporate strategy.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/9492.html